Apc Health LLC

Apc Health LLC was paid $2.32M by Medicaid between Jan 2018 and Nov 2024, across 43 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 22% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#38 of 436

Median peer was paid$17K

This provider vs. median135×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	27,152	$148K
2019	19,825	$300K
2020	19,191	$269K
2021	64,771	$889K
2022	34,342	$652K
2023	3,774	$60K
2024incomplete	555	$3K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	22%	8,458	7,874	$504K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	8.8%	2,573	2,228	$205K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	6.3%	7,756	7,287	$147K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	4.5%	927	900	$104K
80348		3.6%	5,610	5,354	$84K
80321		3.1%	4,916	4,669	$71K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	2.8%	4,031	3,762	$65K
80363		2.7%	4,871	4,655	$64K
80325		2.5%	3,832	3,677	$57K
80333		2.3%	2,998	2,851	$53K
83992		2.1%	5,574	5,317	$48K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	1.9%	3,004	2,738	$45K

31 more codes

G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.9%	2,190	$44K
80346		1.9%	5,602	$43K
80361		1.8%	5,605	$43K
80354		1.8%	5,589	$42K
80356		1.8%	5,534	$42K
80365		1.8%	5,649	$41K
80358		1.7%	5,645	$40K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.7%	2,719	$39K
80373		1.7%	5,587	$39K
80353		1.6%	5,646	$38K
80372		1.6%	5,186	$38K
80370		1.6%	2,419	$38K
80367		1.6%	4,983	$37K
80359		1.5%	5,228	$35K
80366		1.5%	4,999	$35K
80355		1.4%	5,403	$34K
80336		1.4%	3,570	$33K
80368		1.3%	4,253	$29K
80357		1.3%	3,967	$29K
80323		1.2%	3,719	$28K
80349		1.2%	3,839	$28K
80345		1.1%	3,959	$24K
80360		1.0%	3,393	$24K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	607	$12K
80324		<1%	1,695	$10K
80369		<1%	1,879	$9K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	2,150	$8K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	1,900	$7K
80332		<1%	996	$4K
80335		<1%	495	$1K
80362		<1%	654	$851.10

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialNATH, ROHAN (BILLING MANAGER)